Bronchoscope market remains fragmented as Olympus leads in 2024

The bronchoscope market is still spread across many medical device makers, but Olympus held the top global sales position in 2024 with a 3% share. The latest market update points to robotic systems, single-use devices, AI imaging and portable bronchoscopy as the main competitive shifts shaping buying decisions and investment plans.

Why it matters: - Bronchoscopy is moving toward safer, faster and more precise lung diagnostics. - The competitive fight is centered on infection prevention, visualization quality and easier-to-use devices. - Hospitals and outpatient providers are pushing demand for tools that improve procedural accuracy and reduce risk. - Investors and suppliers are watching the segment for growth tied to minimally invasive pulmonary care and digital imaging.

What happened: - The Business Research Company said Olympus Corporation led global bronchoscope sales in 2024 with a 3% market share. - The market research firm identified the bronchoscope market as fairly fragmented, with the top 10 companies accounting for 16% of revenue in 2024. - The report listed major players including Fujifilm Holdings Corporation, Ambu A/S, Karl Storz Endoscopy SE & Co. KG, Boston Scientific Corporation, Medtronic plc, Richard Wolf GmbH, Teleflex Incorporated, Cook Medical LLC and CONMED Corporation. - The report said advanced robotic bronchoscopy is one of the most important market trends. - TidalHealth Nanticoke launched an advanced robotic bronchoscopy system using the Ion platform in September 2024. - The report also highlighted single-use bronchoscope adoption, AI integration, high-definition visualization, strategic collaborations and portable bronchoscopy systems as key strategies. - The report included a free sample request and a detailed market report link: Request a free sample and Read the full report.

The details: - Olympus’ endoscopic solutions segment covers bronchoscopes, imaging systems, visualization platforms and pulmonary diagnostic technologies. - The report said that portfolio supports clinical precision, procedural efficiency, enhanced visualization and respiratory disease management. - The top 10 companies named by the report and their reported shares were Olympus at 3%, Fujifilm at 2%, Ambu at 2%, Karl Storz at 2%, Boston Scientific at 2%, Medtronic at 1%, Richard Wolf at 1%, Teleflex at 1%, Cook Medical at 1% and CONMED at 1%. - The report said moderate entry barriers come from medical device compliance rules, imaging advances, precision engineering and specialized endoscopy manufacturing. - The report said leading companies are building market positions through diversified bronchoscopy portfolios, hospital partnerships, global distribution and continued innovation in disposable and visualization technologies. - Major raw material suppliers listed in the report include Corning Incorporated, DSM Biomedical, Covestro AG, SABIC, Solvay SA, DuPont de Nemours Inc., TE Connectivity Ltd., Nitto Denko Corporation, SCHOTT AG, ZEISS Group, Molex LLC, Heraeus Holding GmbH, Fujikura Ltd., Lubrizol Corporation, Saint-Gobain Life Sciences, TEKNI-PLEX Inc., Asahi Kasei Corporation, Mitsubishi Chemical Group Corporation, Avient Corporation and W. L. Gore & Associates Inc. - Major wholesalers and distributors named in the report include Cardinal Health Inc., Owens & Minor Inc., Henry Schein Inc., McKesson Corporation, Medline Industries LP, Cencora, NDC Inc., Concordance Healthcare Solutions LLC, CME Corp., DiaMedical USA Equipment LLC, Whittemore Enterprises Inc., Mediq BV, PartsSource Inc., US Med-Equip Inc., Hospital Services Limited, Medipost Co. Ltd., Praxisdienst GmbH, Thermo Fisher Scientific Inc., Avantor VWR and Cole-Parmer Instrument Company LLC. - Major end users listed in the report include Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, HCA Healthcare Inc., Kaiser Permanente, Mount Sinai Health System, Cedars-Sinai Medical Center, Singapore General Hospital, Bumrungrad International Hospital, University Hospital Zurich, Charité – Universitätsmedizin Berlin, King Faisal Specialist Hospital & Research Centre, Asan Medical Center, NewYork-Presbyterian Hospital and NHS Foundation Trust hospitals.

Between the lines: - The small share held by the leader shows no single company dominates the market. - That fragmentation suggests competition is being won through technology, not scale alone. - Robotic and AI-enabled systems point to a market moving beyond basic airway inspection toward higher-precision intervention. - Single-use products also reflect stronger infection-control expectations after years of heightened attention to device sterility.

What's next: - The report expects product innovation, strategic collaborations and healthcare infrastructure expansion to strengthen leading companies. - Demand should rise for advanced pulmonary diagnostics, infection control solutions, outpatient bronchoscopy and better procedural efficiency. - The Business Research Company said its 2026 report updates add market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - The company said future bronchoscopy competition will likely center on visualization quality, robotic navigation, single-use adoption and point-of-care portability.